(Q80421968)
Statements
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients (English)
Jos H Beijnen
Isa E L M Kuppens
Els O Witteveen
Roxanne C Jewell
Sandra A Radema
Elaine M Paul
Steve G Mangum
Emile E Voest